

SEVNFAAEF, SEVKFLAEF, and SEVNFLAEF].

107. (amended) The screening kit of claim 106, wherein said β -secretase-cleavable fragment [is] has a sequence selected from the group consisting of SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95 and SEQ ID NO: 96 [SEVKMDAEF (P5-P4'wt), SEVNLDAEF (sw), SEVKLDAEF, SEVKFDAEF, SEVNFDAEF, SEVKMAAEF, SEVNLADEF, SEVKLAAEF; SEVKMLAEF, SEVNLLAEF, SEVKLLAEF, SEVKFAAEF, SEVNFAAEF, SEVKFLAEF, and SEVNFLAEF].

REMARKS

The corrections and additions to the specification requested herein are corrections needed to conform the specification to the Sequence Listing, as explained below.

The correction to line 31 of page 8 is required, since SEQ ID NO: 78 was originally used twice to refer to two different sequences. Correction was made to identify the second of these sequences as SEQ ID NO: 98. Accordingly, the descriptor of SEQ ID NO: 98 was also added at page 12 after line 26.

The descriptor of SEQ ID NO: 51 at page 11, lines 4-5 was modified to correctly identify the sequence cited.

The descriptor of SEQ ID NO: 54 at page 11, line 8 was modified to better describe the peptide sequence.

The descriptor of SEQ ID NO: 73 was modified to remove the recited sequence, which correctly describes SEQ ID NO: 72 (obvious from the length of the sequence), but which is superfluous in view of the Sequence Listing.

The descriptors of SEQ ID NOS: 99-102 were added at page 12, in view of their addition to the sequence listing, as described with reference to Table 3, below.

The Sequence identifiers SEQ ID NOS. 99-102 were added to Table 3, page 31, in order to describe these sequences in the Sequence Listing.

Correction of the sequence recited at page 30, line 16 (SEQ ID NO: 56) was made to correct an obvious error. The internal peptide is correctly shown in FIG. 5 (block described as "internal peptide sequence") with a "G" (glycine) in position 2 thereof. The transcription error was inadvertant and without deceptive intent.

The insertion of sequence identifiers at lines 21 and 22 of page 68 were necessary to comply with the requirements 37 C.F.R. §1.821.

Claims 47, 77, 85 and 106 have been amended to insert sequence identifiers in the place of the recited peptide fragment sequences.

Applicants submit that no new matter is added by the foregoing amendments to the specification. Accordingly, entry of this amendment is respectfully requested.

Respectfully submitted,



Nina M. Ashton
Registration No. 37,273

CUSTOMER NUMBER: **21835**
ELAN PHARMACEUTICALS, INC.
800 Gateway Blvd
South San Francisco, California 94080
Telephone: (650) 616-2639
Telefax: (650) 553-7165